graft versus host disease
Conditions
Interventions
experimental group:Decitabine containing condition regimen
control group:With no intervention of decitabine
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years; 2. Meet the diagnostic criteria for AML (2016WHO) and have allo-HSCT indications, or meet the MDS diagnostic criteria (2016WHO) and have allo-HSCT indications, with available donors, and no contraindications for transplantation; 3. Patients who are suitable for conventional Blu/Flu conditioning regimen; 4. No serious diseases of the heart, liver, kidney, lung and other important organs, no rheumatic immune diseases, endocrine diseases and other tumors, no history of chronic digestive tract diseases; 5. No smoking and alcohol addiction, history of drug abuse, body mass index (BMI) <27kg/m^2; 6. Regular follow-up, with good compliance, agree to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Second and above transplant recipients; 2. Patients with chronic kidney disease, pulmonary interstitial disease, etc. who need to take other immune preparations for a long time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of GVHD;Leukemia recurrence rate;Overall survival during follow-up;Disease free survival;Median follow up time; | — |
Countries
China
Contacts
Public ContactRen Hanyun
Peking University First Hospital
Outcome results
None listed